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Abstract
Background: The current study was carried out to determine whether fasudil hydrochloride (fasudil), a Rho-kinase
inhibitor, has myocardial postconditioning (PostC) activity under hyperglycemia as well as normoglycemia, and if
so, whether the effects could be mediated by mitochondrial ATP-sensitive potassium (m-KATP) channels.
Methods: Male Sprague-Dawley rats were anesthetized with sodium pentobarbital. After opening the chest, all rats
underwent 30-min coronary artery occlusion followed by 2-h reperfusion. The rats received low-dose (0.15 mg/kg)
or high-dose (0.5 mg/kg) fasudil or diazoxide, an m-KATP channel opener, at 10 mg/kg, just before reperfusion
under normoglycemic or hyperglycemic conditions. In another group, rats received 5-hydroxydecanoic acid (5HD),
an m-KATP channel blocker, at 10 mg/kg, before high-dose fasudil. Myocardial infarct size was expressed as a
percentage of area at risk (AAR).
Results: Under normoglycemia, low-dose and high-dose fasudil and diazoxide reduced myocardial infarct size (23
± 8%, 21 ± 9% and 21 ± 10% of AAR, respectively) compared with that in the control (42 ± 7%). Under
hyperglycemia, low-dose fasudil (40 ± 11%) and diazoxide (44 ± 14%) could not exert this beneficial effect, but
high-dose fasudil reduced myocardial infarct size in the same manner as under normoglycemia (21 ± 13%). 5HD
prevented fasudil-induced reduction of myocardial infarct size (42 ± 13%).
Conclusion: Fasudil induces PostC against myocardial infarction via activation of m-KATP channels in the rat.
Although hyperglycemia attenuates the PostC, high-dose fasudil can restore cardioprotection.
Keywords: Hyperglycemia, Postconditioning, Myocardial Infarction, Fasudil, Mitochondrial KATP channels
Introduction
Rho-kinase, a ubiquitously expressed serine-threonine
protein kinase that is involved in diverse cellular func-
tions, may play a pivotal role in cardiovascular diseases
such as vasospastic angina, ischemic stroke and heart
failure [1]. Some reports showed that fasudil hydrochlor-
ide (fasudil), a Rho-kinase inhibitor, had beneficial
effects in ischemic heart disease. A double-blind pla-
cebo-controlled trial showed that fasudil increased the
ischemic threshold of angina patients during exercise
with a trend toward increased exercise duration [2].
Intracoronary administration of fasudil increased oxygen
saturation in coronary sinus vein, and ameliorated
pacing-induced myocardial ischemia in patients with
effort angina [3]. Rho-kinase was activated in ischemic
myocardium, and a Rho-kinase inhibitor lead to the
activation of the phosphatidylinositol 3-kinase (PI3K)/
Akt/eNOS signaling pathway, resulting in precondition-
ing (PreC) or postconditioning (PostC) [4,5]. Further-
more, hydroxyfasudil was also reported to activate ATP-
sensitive potassium (KATP) channels via inhibition of
Rho-kinase during myocardial remote peri-conditioning
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reproduction in any medium, provided the original work is properly cited.[6]. However, it is not clear whether mitochondrial
KATP (m-KATP) channels mediate the Rho-kinase inhi-
bitor-induced PostC.
Hyperglycemia is an important predictor and a risk
factor of cardiovascular morbidity and mortality in
patients with and without diabetes mellitus [7-9]. A
number of studies have shown that the cardioprotective
effects of pharmacological PreC and PostC are impaired
by hyperglycemia [10-16]. Although the detailed
mechanisms are unclear, it has been suggested that the
loss of cardioprotection by hyperglycemia might be
associated with several mechanisms, namely, generation
of large quantities of reactive oxygen species (ROS),
inhibition of protective signaling mechanisms, down-
regulation of endothelial nitric synthase (eNOS),
reduced activation and availability of protective mole-
cules, coronary vascular endothelial dysfunction, and/or
impairment in the function of m-KATP channels
[11-13,17,18]. However, the effect of hyperglycemia on
the Rho-kinase inhibitor-induced myocardial protection
against ischemic reperfusion injury is unknown.
The present study was carried out to clarify whether
fasudil has PostC activity and, if so, whether the cardio-
protective effect is mediated by m-KATP channels and
attenuated by hyperglycemia.
Materials and methods
All experimental procedures and protocols described in
t h i ss t u d yw e r ea p p r o v e db yt h eI n s t i t u t i o n a lA n i m a l
Care and Use Committee of Nagasaki University School
of Medicine.
Drugs
Fasudil was purchased from Asahikasei Pharma (Tokyo,
Japan). 5-hydroxydecanoic acid (5-HD), an m-KATP
channel blocker, diazoxide, an m-KATP channel opener,
patent blue dye, and 2,3,5-triphenyltetrazolium chloride
(TTC) were purchased from Sigma (St. Louis, MO,
USA).
General preparation
The instrumental methods used were as described in
our previous report [19]. Male Sprague-Dawley (SD)
rats weighing between 350 and 550 g were anesthetized
with sodium pentobarbital (a 50 mg/kg intraperitoneal
bolus followed by an intravenous infusion of 10-20 mg/
kg/h). The rats were adequately sedated to ensure that
pedal and palpebral reflexes were absent throughout the
experimental protocol. Catheters were inserted into the
right jugular vein for fluid or drug administration and
the right carotid artery for measurement of arterial
blood pressure. After tracheotomy had been performed,
the trachea was intubated with a cannula connected to a
s m a l la n i m a lv e n t i l a t o r( SAR-830 CWE, PA, USA), and
the lungs were ventilated with pure oxygen. Arterial
blood gas pH was maintained within a physiological
range by adjusting the respiratory rate and tidal volume
throughout the experiment. A left thoracotomy was per-
formed in the fifth intercostal space, and the pericar-
dium was opened. A 7-0 prolene ligature was placed
around the proximal left anterior descending coronary
artery (LAD) and vein in the area immediately below
the left atrial appendage. The ends of the suture were
threaded through a small plastic tube to form a snare
for reversible LAD occlusion. Coronary artery occlusion
was produced by clamping the snare onto the epicardial
surface of the heart and was confirmed by the appear-
ance of epicardial cyanosis. Reperfusion was achieved by
loosening the snare and was verified by observing an
epicardial hyperemic response. Hemodynamics were
continuously monitored with a transducer (sck-9082,
Becton Dickinson, Tokyo, Japan) and a blood pressure
amplifier (AP-641 G, Nihon-Kohden, Tokyo, Japan) and
shown on a polygraph system (RMP-6018, Nihon-Koh-
den, Tokyo, Japan).
Experimental protocol
The classification of experimental groups is shown in
Table 1, and the experimental design is illustrated in
Figure 1. All rats underwent 30-min LAD occlusion fol-
lowed by 2-h reperfusion. The rats were randomly
assigned to one of 10 groups (n = 10 for each). Six of
them were under normoglycemic conditions, and 4 of
them were under hyperglycemic conditions. The hyper-
glycemia was produced with continuous infusion of 50%
glucose in water starting at 15 min before LAD occlu-
sion and lasting until 60 min after reperfusion. The tar-
get hyperglycemia was 350 mg/dl.
In 4 normoglycemic groups, rats received saline as
control (group CON), low-dose fasudil (0.15 mg/kg;
group LF), high-dose fasudil (0.5 mg/kg; group HF) or
diazoxide (10 mg/kg; group DIA) by i.v. bolus just
before reperfusion.
In 2 normoglycemic groups, rats received 5HD, at 10
mg/kg, by i.v. bolus at 5 min before reperfusion followed
by saline (group 5HD) or high-dose fasudil (group HF +
5HD) by i.v. bolus just before reperfusion.
In 4 hyperglycemic groups, rats received saline (group
HG), low-dose fasudil (group LF + HG), high-dose fasu-
dil (group HF + HG) or daizoxide (group DIA + HG).
The dose of fasudil was set on the basis of the clinical
dosage for cerebral vasospasm after subarachnoid
hemorrhage [20] as determined in our preliminary
study. The dose of diazoxide was set on the basis of our
preliminary study, which showed that 10 mg/kg but not
3 mg/kg diazoxide reduces infarct size (data not shown).
T h ed o s eo f5 H Dw a ss e to nt h eb a s i so fap r e v i o u s
study [19].
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Blood samples were collected to measure blood glucose in
each group. The blood glucose concentration was deter-
mined by the glucose oxidase method using a blood glu-
cose meter (Glutest Ace, Sanwa Kagaku Kenkyusho,
Nagoya, Japan). Samples were taken before starting glu-
cose infusion, just before ischemia, just after starting
reperfusion, and at 1 and 2 h after starting reperfusion.
Determination of infarct size
Myocardial infarct size was measured as previously
described [21]. Briefly, at the end of each experiment,
the LAD was reoccluded, and patent blue dye was admi-
nistered intravenously to stain the normal region of the
left ventricle (LV), and the heart was rapidly excised. LV
tissue was isolated and cut into approximately ten cross-
sectional pieces of equal thickness. The nonstained LV
area at risk (AAR) was separated from surrounding
blue-stained LV normal zone, and both regions were
separately incubated at 37°C for 15 min in 1% TTC in
0.1 M phosphate buffer adjusted to pH 7.4. The tissues
were fixed overnight in 10% formaldehyde. AAR and
blue-stained LV normal zone region were weighed for
determination of AAR/LV. TTC stains living tissue a
Table 1 The classification of experimental groups
Groups Treatments
CON Saline, i.v. bolus just before reperfusion.
LF Low-dose fasudil (0.15 mg/kg), i.v. bolus just before reperfusion.
HF High-dose fasudil (0.5 mg/kg), i.v. bolus just before reperfusion.
DIA Diazoxide (10 mg/kg), i.v. bolus just before reperfusion.
HG Saline, i.v. bolus just before reperfusion, and continuous infusion of 50% glucose in water starting at 15 min before LAD occlusion and
lasting until 60 min after reperfusion. The target blood glucose concentration was 350 mg/dl.
LF + HG Same as group HG except for low-dose fasudil (0.15 mg/kg) in place of saline.
HF + HG Same as group HG except for low-dose fasudil (0.5 mg/kg) in place of saline.
DIA +
HG
Same as group HG except for diazoxide (10 mg/kg) in place of saline.
5HD 5HD (10 mg/kg), i.v. at 5 min before reperfusion followed by saline, i.v. bolus just before reperfusion.
HF +
5HD
Same as group 5HD except for high-dose fasudil (0.5 mg/kg) in place of saline.
Figure 1 A schematic illustration of the experimental protocols.
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Page 3 of 9deep red color, but necrotic tissue is TTC-negative and
appears white within the AAR slices. Each slice was
scanned at 1,200 dpi with a commercial scanner (Canos-
can LiDE 60; Canon, Japan), and infarcted and nonin-
farcted areas were measured using an image analysis
program. Myocardial infarct size is expressed as a per-
centage of the AAR.
Statistical analysis
Statistical analyses of hemodynamic data and blood glu-
cose concentrations within and between groups were
performed with analysis of variance for repeated mea-
sures followed by Dunnett’s test. Inter-group differences
in body weight, age, LV weight, AAR weight, the ratio
of AAR to LV and the ratio of infarct size to AAR were
analyzed using one-way analysis of variance followed by
the Student-Newman-Keuls test. Statistical significance
was defined as P < 0.05. All values are expressed as
mean ± SD. Statistical analysis was performed using
SPSS 15.0 software (SPSS Japan, Tokyo, Japan) or
GraphPad Prism 5.0 (GraphPad Software, San Diego,
CA).
Results
Hemodynamics
There were no significant differences in body weight or
age among the groups. Hemodynamic data for heart
rate (HR) and mean blood pressure (MBP) are shown in
Table 2. There were no significant differences either
within groups or among groups in HR or MBP at any
measurement point.
Infarct size
There were no significant differences in LV weight, AAR
weight or the ratio of AAR to total LV mass among the
groups (Table 3). Infarct sizes expressed as a percentage
of AAR are shown in Figures 2, 3. In groups LF, HF and
DIA, the infarct sizes were significantly reduced com-
pared with that in group CON (Figure 2). In groups LF
+ HG and DIA + HG, the infarct sizes were similar to
that in group CON (Figure 2). In contrast, the infarct
size in group HF + HG was significantly less than that
in group CON. In group HF + 5HD, the infarct size was
similar to that in group CON (Figure 3).
Blood glucose concentrations
As shown in Table 4, blood glucose concentrations at
baseline did not differ among the groups. Blood glucose
concentrations did not change significantly over time in
normoglycemic groups. In hyperglycemic groups, blood
glucose concentrations at just before ischemia, just after
starting reperfusion and 1 h after starting reperfusion
were significantly higher than those at baseline and 2 h
after reperfusion. There were no significant differences
in blood glucose concentrations among the hyperglyce-
mic groups at any measured point.
Table 2 Systemic hemodynamic
Baseline Occlusion 20 min Reperfusion 20 min 1 h after reperfusion 2 h after reperfusion
CON HR 112 ± 15 114 ± 20 120 ± 13 109 ± 15 101 ± 14
MAP 423 ± 30 420 ± 34 425 ± 36 410 ± 38 407 ± 35
LF HR 114 ± 12 119 ± 12 113 ± 14 104 ± 9 96 ± 9
MAP 431 ± 28 427 ± 30 415 ± 34 405 ± 35 393 ± 35
HF HR 107 ± 30 111 ± 28 106 ± 26 114 ± 25 115 ± 18
MAP 408 ± 37 381 ± 57 395 ± 38 404 ± 36 392 ± 52
DIA HR 104 ± 16 100 ± 20 97 ± 21 106 ± 28 106 ± 28
MAP 403 ± 62 399 ± 66 388 ± 79 393 ± 69 400 ± 61
5HD HR 104 ± 16 100 ± 20 102 ± 18 114 ± 25 110 ± 24
MAP 394 ± 44 384 ± 52 385 ± 50 370 ± 32 407 ± 53
HF + 5HD HR 108 ± 24 107 ± 27 112 ± 28 95 ± 27 99 ± 20
MAP 404 ± 69 392 ± 51 392 ± 60 384 ± 69 397 ± 47
HG HR 107 ± 20 91 ± 15 116 ± 25 113 ± 19 104 ± 15
MAP 409 ± 33 403 ± 34 409 ± 36 396 ± 30 397 ± 40
LF + HG HR 101 ± 12 93 ± 16 96 ± 19 106 ± 20 110 ± 17
MAP 406 ± 42 388 ± 58 386 ± 60 398 ± 55 408 ± 53
HF + HG HR 100 ± 29 104 ± 27 115 ± 25 108 ± 24 89 ± 30
MAP 407 ± 65 407 ± 28 383 ± 64 376 ± 64 380 ± 76
DIA + HG HR 106 ± 24 104 ± 16 102 ± 21 97 ± 18 104 ± 23
MAP 389 ± 48 398 ± 53 396 ± 30 389 ± 45 383 ± 58
Data are mean ± SD, and n = 10 for each.
HR = heart rate (beats/min); MAP = mean arterial pressure (mmHg); CON = control; LF or HR = 0.15 or 0.5 mg/kg fasudil hydrochloride, DIA = 10 mg/kg
diazoxide; 5HD = 5-hydroxydecanoic acid; HG = hyperglycemia.
Ichinomiya et al. Cardiovascular Diabetology 2012, 11:28
http://www.cardiab.com/content/11/1/28
Page 4 of 9Discussion
The present results show that fasudil induces postcondi-
tioning against myocardial infarction via m-KATP chan-
nels in the rat, and that hyperglycemia prevents fasudil-
and diazoxide-induced postconditioning, whereas high-
dose fasudil can restore cardioprotection even under
hyperglycemia.
In the present results, both high and low doses of fas-
udil produced equivalent reductions of myocardial
infarct size under normoglycemia. However, hyperglyce-
mia completely abolished the protective effect of the low
dose, but not the high dose of fasudil. Fasudil is clini-
cally used in doses of 30 mg/30 min intravenous infu-
sion three times a day for cerebral vasospasm after
subarachnoid hemorrhage [20], and 60 mg/60 min intra-
venous infusion twice daily for acute ischemic stroke
[22]. Thus, the high dose used in the present study is
relevant to the clinical dose, and it is indicated that fas-
udil at a clinical dose could induce PostC even under
hyperglycemia.
Kersten et al. [12] showed that PreC evoked by 2.5
mg/kg but not 5 mg/kg diazoxide was blocked by hyper-
glycemia, and they assumed that the blockage of m-
KATP channels was the underlying mechanism of the
lack of myocardial protectionb yv o l a t i l ea n e s t h e t i c s
Table 3 Left ventricular area at risk and infarct size
AAR/LV (%) IS/AAR (%)
CON 51 ± 9 42 ± 7
LF 46 ± 9 23 ± 8*
HF 52 ± 9 21 ± 9*
DIA 46 ± 7 21 ± 10*
5HD 48 ± 8 46 ± 12
HF + 5HG 44 ± 7 42 ± 13
HG 43 ± 13 42 ± 10
LF + HG 50 ± 9 40 ± 11
HF + HG 45 ± 7 21 ± 13*
DIA + HG 48 ± 9 44 ± 14
Date are mean ± SD, and n = 10 for earch.
CON = control; LF or HF = 0.15 or 0.5 mg/kg fasudil hydrochloride; DIA = 10
mg/kg diazoxide; 5HD = 5-hydroxydecanoic acid; HG = hyperglycemia.
*Significantly (p < 0.05) different from control.
Figure 2 Myocardial infarct size expressed as a percentage of the left ventricular area at risk. Hyperglycemia (HG) group was
administered 50% glucose during occlusion and until 1 h after reperfusion. CON received saline just before reperfusion; LF or HF, 0.15 or 0.5
mg/kg fasudil hydrochloride; and DIA, 10 mg/kg diazoxide. Data are mean ± SD and n = 10 for each. *Significantly (p < 0.05) different from
control.
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that hyperglycemia raised the threshold of levosimen-
dan-induced PostC [23], and it is suggested that levosi-
mendan-induced PostC involves the activation of m-
KATP channels [24]. In the present results, low-dose
fasudil- and diazoxide-induced PostC were attenuated
by hyperglycemia, and 5-HD inhibited the fasudil-
induced PostC. Therefore, it is likely that fasudil-
Figure 3 Myocardial infarct size expressed as a percentage of the left ventricular area at risk. 5HD group was administered 10 mg/kg 5-
hydroxydecanoic acid at 5 min before reperfusion. CON received saline just before reperfusion; HF, 0.5 mg/kg fasudil hydrochloride.
*Significantly (p < 0.05) different from control.
Table 4 Blood glucose concentration (mg/dl)
Baseline Before ischemia Just after reperfusion 1 h after reperfusion 2 h after reperfusion
CON 88 ± 15 91 ± 19 112 ± 27 105 ± 32 101 ± 20
LF 95 ± 11 109 ± 14 122 ± 26 118 ± 26 100 ± 23
HF 89 ± 17 87 ± 13 111 ± 33 93 ± 35 95 ± 26
DIA 90 ± 14 88 ± 14 107 + 31 120 ± 35 107 ± 28
5HD 89 ± 12 85 ± 16 101 ± 28 108 ± 18 111 ± 28
HF + 5HD 87 ± 8 86 ± 9 105 ± 24 101 ± 26 104 ± 24
HG 92 ± 12 349 ± 32*
† 360 ± 50*
† 353 ± 28*
† 100 ± 39
LF + HG 92 ± 13 338 ± 24*
† 378 ± 57*
† 327 ± 29*
† 105 ± 42
HF + HG 92 ± 12 341 ± 25*
† 374 ± 52*
† 337 ± 47*
† 110 ± 28
DIA + HG 91 ± 13 349 ± 22*
† 350 ± 53*
† 353 ± 28*
† 106 ± 37
Data are mean ± SD, and n = 10 for each.
CON = control; LF or HF = 0.15 or 0.5 mg/kg fasudil hydrochloride; DIA = 10 mg/kg diazoxide; 5HD = 5-hydroxydecanoic acid; HG = hyperglycemia.
*Significantly (p < 0.05) different from baseline.
†Significantly (p < 0.05) different from control.
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could be attenuated by hyperglycemia.
Zaho et al. [6] reported that the peri-conditioning sti-
mulus of hydroxyfasudil was abrogated by glibenclamide,
a non-selective KATP channel blocker, and suggested
that activation of KATP channels could be mediated by
Rho-kinase inhibition. Although some studies on PostC
that targeted KATP channels generated negative results
[25,26], a number of studies have revealed an obligatory
role of m-KATP channels in both ischemic and pharma-
cological PostC [27-31]. Wolfrum et al. [4] reported that
the Rho-kinase inhibition led to the activation of PI3K/
Akt/eNOS pathway and PreC. Hamid et al. [5] showed
that inhibition of Rho-kinase by Y27632, a structurally
unrelated inhibitor of hydroxyfasudil, at reperfusion
onset limited infarct size through an Akt/eNOS-depen-
dent mechanism. Consequently, it is suggested that
Rho-kinase acts as a negative regulator of PI3K activa-
tion, and modulates the protective effect via PI3K/Akt/
eNOS pathway on myocardial PreC and PostC. Some
kinds of pharmacological PostC were shown to depend
on PI3K/Akt/eNOS pathway with a target downstream
of m-KATP channels [27,28]. Therefore, it is likely that
fasudil could induce the opening of m-KATP channels
by up-regulating PI3K/Akt/eNOS pathway, resulting in
induction of PostC.
Rho kinase activity is involved in diabetic endothelial
dysfunction, and regulation of Rho kinase signaling is
important for cellular function, such as contraction,
mortality, proliferation, apoptosis [32]. Correspondingly,
Rho-kinase is known to be activated in ischemic myo-
cardium, and inhibition of Rho-kinase activity is a mat-
ter of great interest on myocardial protection against
ischemic reperfusion injury [33]. However, there are few
reports on the effect of hyperglycemia on the myocardial
Rho-kinase activity during ischemia-reperfusion. It was
shown that exposure of endothelial cells, renal glomeru-
lus and cardiac fibroblasts to hyperglycemia increases
Rho-kinase activity [34-37], and that the Rho-kinase
activity occurred in a glycemic concentration-dependent
manner [34,37]. Furthermore, the protective effect of
Rho-kinase inhibitor depends on the dose under hyper-
glycemia [34,35,37]. Thus, it is likely that hyperglycemia
could increase the myocardial Rho-kinase activity during
ischemia-reperfusion, and raise the threshold of fasudil-
induced PostC.
Hyperglycemia is an important predictor and a risk
factor of cardiovascular morbidity and mortality [7-9],
and pharmacological cardioprotection against ischemia-
reperfusion injury is impaired by hyperglycemia, inde-
pendent of diabetes [10-16]. PostC is considered to be
more feasible than PreC for clinical application, and
would be useful in unpredictable myocardial ischemia-
reperfusion injury. Neverth e l e s s ,t h e r ea r eo n l yaf e w
reports concerning pharmacological PostC under hyper-
glycemia. Raphael et al. [11] showed that hyperglycemia
inhibited PostC provided by isoflurane, and that the
effect was mediated via modulation of PI3K/Akt/eNOS
signaling. Huhn et al. [10] reported that sevoflurane-
induced PostC was blocked by hyperglycemia, but the
inhibition of mitochondrial permeability transition pore
with cyclosporine A could reverse this loss of cardiopro-
tection. Therefore, the present report is the first
describe about Rho-kinase inhibitor-induced PostC
under hyperglycemia.
Przyklen et al. [38] reported that diabetic hearts were
refractory to ischemic PostC, but the effect in the type 1
diabetic model was reversed by restoration of normogly-
cemia. Whereas, Drenger et al. [27] showed that the
protective effect of ishemic and sevoflurane PostC were
not relived by insulin-induced normoglycemia in dia-
betic rats. Tsang et al. [39] reported that it was neces-
sary to increase the ischemic PreC stimulus to achieve
the threshold for cardioprotection and a critical level of
Akt phosphorylation to mediate myocardial protection
in diabetes. Furthermore, rats with type 1 diabetes for 4
weeks showed ischemic PreC weaker than normal rats,
but there was no cardioprotection in the rats for 8
weeks [40]. These finding suggested that the threshold
for cardioprotection in diabetes will gradually increase
with the prolongation of hyperglycemic time. Therefore,
it is likely that the threshold of PostC in the diabetic
animals or in animals exposed to longer periods of
hyperglycemia is higher than acute hyperglycemia.
Marinovic et al. [41] reported that sarcolemma KATP
(s-KATP) channels act as an effector and m-KATP
channels play a dual role as a trigger and an effector in
cardioprotection by isoflurane-induced PreC against oxi-
dative stress. Furthermore, Yang et al. [42] showed that
KR31761, a new KATP channel opener, exerted PreC in
rats, and both 5-HD and HMR-1098, an s-KATP chan-
nel blocker, prevents the cardioprotective effects. Chen
et al. [43] reported that s-KATP channels were
decreased in diabetes and under hyperglycemia, and it
lead to result in desensitization of some KATP channel
drugs. Thus, there is possibility that cardiprotection via
s-KATP channels is attenuated under hyperglycemia.
However, mechanism for s-KATP channels dependent
PreC and PostC is not clarified, and there are few
reports about s-KATP channels involved with rho-
kinase. Further research is needed to elucidate the mole-
cular mechanisms contributing to this cardioprotective
effect.
Conclusion
Fasudil induces PostC against myocardial infarction in
the rat. This protective effect of fasudil is mediated by
activation of m-KATP channels. Although
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PostC, high-dose fasudil could preserve the protective
effect.
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